NAFDAC Debunks Claim that Camosunate Has Been Banned in Nigeria

By our Reporter

The National Agency for Food and Drug Administration and Control (NAFDAC) has debunked social media claims that Camosunate, an antimalarial medicine containing artesunate and amodiaquine, has been banned in Nigeria.

The agency, in a press release signed by NAFDAC Director-General and Chief Executive Officer, Professor Mojisola Adeyeye dated November 21, 2026, said it had never banned Camosunate or medicines containing the artesunate-amodiaquine combination, describing the circulating claim as false.

NAFDAC, however, acknowledged that some symptoms mentioned in the viral claim may be associated with known side effects of Camosunate, including nausea, vomiting, diarrhoea, abdominal pain, headache, dizziness, drowsiness and loss of appetite.

It urged members of the public and healthcare professionals to report suspected adverse drug reactions for proper assessment, stressing that such reports could be submitted through the NAFDAC Med Safety App, available on Android and iOS devices, or at the nearest NAFDAC office.

The agency appealed to the public to stop circulating the misinformation, urging those who had already shared the claim to disseminate its clarification through the same channels to help counter misinformation and prevent unnecessary public concern.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top